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Abstract.	 The	 human	 genome	 is	 replete	 with	 repetitive	 DNA	 sequences	 that	 can	 fold	 into	
thermodynamically	stable	secondary	structures	such	as	hairpins	and	quadruplexes.	Cellular	enzymes	
exist	to	cope	with	these	structures	whose	stable	accumulation	would	result	in	DNA	damage	through	
interference	 with	 DNA	 transactions	 such	 as	 transcription	 and	 replication.	 Therefore,	 chemical	
stabilization	of	secondary	DNA	structures	offers	an	attractive	way	to	foster	DNA	transaction-associated	
damages	 to	 trigger	cell	death	 in	proliferating	cancer	cells.	While	much	emphasis	has	been	recently	
given	 to	 DNA	 quadruplexes,	 we	 focused	 here	 on	 three-way	 DNA	 junctions	 (TWJ)	 and	 report	 on	 a	
strategy	to	identify	TWJ-targeting	agents	through	a	combination	of	in	vitro	techniques	(TWJ-Screen,	
PAGE,	FRET-melting,	ESI-MS,	dialysis	equilibrium	and	SRB	assays).	We	designed	a	complete	workflow	
and	 screened	 1200	 compounds	 to	 identify	 promising	 TWJ-ligands	 selected	 on	 stringent	 criteria	 in	
terms	of	TWJ	folding	ability,	affinity	and	selectivity.	
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Introduction.		
DNA	transactions	(replication	and	transcription)	are	finely	orchestrated	cellular	processes	that	are	
frequently	 challenged	 by	 situations	 of	 crisis	 notably	 when	 dealing	 with	 damaged	 DNA,	 secondary	
structures	or	in	situations	of	nucleotide	pools	shortage	or	imbalance,	which	can	result	in	DNA	and	RNA	
polymerase	stalling.1,	2	If	persistent,	these	polymerase	arrests	activate	the	DNA	damage	response	that	
includes	DNA	repair	mechanisms	and	that	dictates	cell	tolerance	and	survival.3,	4	Crisis-inducers	can	
lead	 to	 genomic	 instability	 and	eventually	 to	 cell	 death	 if	DNA	 repair	 is	 unsuccessful,	 unfaithful	 or	
generates	toxic	products.	Sources	of	such	situations	can	be	endogenous	(e.g.,	stochastic	nucleotide	
misincorporation,	 reactive	 oxygen	 species	 (ROS)-promoted	 lesions)	 or	 exogenous	 (e.g.,	 irradiation,	
genotoxic	compounds).5,	6	
Several	 anticancer	 therapies	 rely	 on	 genotoxic	 chemicals	 that	 triggers	 covalent	 DNA	 damages	
including	cross-links	(e.g.,	cisplatin),	alkylated	bases	(e.g.,	temozolomide),	or	trapped	topoisomerase	I	
and	II	complexes	(e.g.,	camptothecin	analogues	and	etoposide).7,	8	An	alternative	approach	would	be	
to	consider	chemicals	 capable	of	 stabilizing	DNA	secondary	 structures	 that	might	arise	during	DNA	
transactions.9,	10	Repeated	DNA	sequences	are	 indeed	prone	 to	 fold	 into	higher-order	 structures	 in	
response	 to	 the	 torsional	 stress	 provoked	 by	 the	 progression	 of	 polymerases.	 These	 secondary	
structures	(i.e.,	hairpin,	G-quadruplex,	R-loop,	DNA	junction),	whose	nature	depends	on	the	sequences	
involved	 (i.e.,	 direct	 or	 inverted	 tandem	 repeats),	 represent	 topological	 obstacles	 the	 cellular	
machinery	must	cope	with	efficiently	to	proceed,	mostly	through	the	dedicated	helicases.11	Stabilizing	
these	structures	by	chemicals	thus	represent	an	innovative	way	to	trigger	cell	crisis	and	death	in	cells	
defective	for	genome	maintenance	mechanisms.		
Over	 the	 past	 years,	 most	 emphasis	 has	 been	 given	 to	 G-quadruplexes	 as	 roadblocks	 to	 DNA	
transactions12-14	 but	 also	 as	 new	 and	 promising	 genetic	 switches	 to	 control	 gene	 expression.15,	 16	
Alternatively,	we17-19	and	others20-27	have	invested	efforts	to	study	DNA	junctions	as	druggable	targets,	
chiefly	three-way	DNA	junctions	(TWJ).	We	recently	developed	the	high-throughput	screening	(HTS)	
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assay	TWJ-Screen	that	allows	for	identification	 in	vitro	of	promising	TWJ-interacting	compounds	(or	
TWJ-ligands)	in	vitro.19	To	be	selective,	ligands	must	interact	with	the	structural	peculiarity	of	the	TWJ	
structure,	 that	 is,	 the	branch	point:	 this	 cavity,	 at	 the	very	heart	of	 the	 structure,	 results	 from	the	
convergence	of	the	three	duplex	arms	that	constitute	the	TWJ	(Figure	1A).	Here,	we	kept	on	searching	
for	new	TWJ-ligands	evaluating	1200	candidates	from	3	different	chemical	libraries.	We	then	further	
investigated	the	TWJ-interacting	properties	of	the	best	candidates	via	a	series	of	complementary	 in	
vitro	assays	(PAGE,	FRET-melting,	ESI-MS	and	equilibrium	dialysis)	to	gain	reliable	insights	into	their	
affinity	and	selectivity	for	TWJ.	
	
Results	and	Discussion.		
Selection	 of	 chemical	 libraries	 for	 TWJ-screen	 evaluations.	 To	 assess	whether	 the	 TWJ-Screen	
assay	is	suited	to	screen	wide	collections	of	small-molecule	candidates,	we	used	3	different	chemical	
libraries:	i-	The	Pathogen	Box®,	from	Medicines	for	Malaria	Venture	(MMV).28,	29	This	library,	available	
free	of	charge,	comprises	400	drug-like	molecules	intended	to	be	assayed	against	neglected	tropical	
diseases	including	malaria,	tuberculosis,	toxoplasmosis,	dengue,	etc.	Chemical	structures	can	be	found	
at	https://www.pathogenbox.org/about-pathogen-box/composition.	 ii-	 The	chimiothèque	Nationale	
Essentielle	 (CNE,	version	2017);30	 this	 library	comprises	640	compounds,	either	synthetic	or	natural	
products,	 gathered	 from	different	 French	 laboratories	 under	 the	 authority	 of	 the	 French	Chemical	
Library.	This	library	is	commercially	available;	the	full	list	of	chemicals	cannot	be	shown	due	to	owner	
restriction.	And	iii-	the	so-called	ICMUB	library	comprising	160	compounds	that	have	been	assembled	
by	 our	 group	 through	 national	 and	 international	 collaborations	 over	 the	 years.	 The	 full	 list	 of	
compounds	cannot	be	 shown	due	 to	confidentiality	 issues;	however,	 the	chemical	 structures	of	all	
identified	hits	are	shown	in	Figure	1.	Collectively,	these	3	libraries	represent	a	total	of	1200	candidates,	
which	display	a	very	high	level	of	chemical	diversity.		
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Figure	1.	A.	Schematic	representation	of	the	folding	of	a	TWJ	structure.	B.	TWJ-Screen	results	of	a	library	of	1200	
compounds,	expressed	as	the	%	of	quenched	FAM	fluorescence	of	the	three	strands	mixture	(M)	in	presence	of	
5	mol.	equiv.	candidate	(i.e.,	M-(M+ligand),	Y-axis)	as	a	function	of	the	%	of	FAM-TWJ-S1	fluorescence	measured	
in	presence	of	5	mol.	equiv.	candidate	(i.e.,	FAM-TWJ-S1+ligand,	X-axis).	Experiments	performed	with	0.2	µM	
DNA,	without	or	with	1.0	µM	candidates,	in	10	mM	lithium	cacodylate	plus	10	mM	KCl/90	mM	LiCl,	pH	7.2	at	37	
°C	for	1	h.	C.	Chemical	structures	of	the	top	15	ligands	identified	through	TWJ-Screen	evaluation.	
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Table	1.	Top	TWJ-ligands	selection	on	the	basis	of	TWJ-Screen,	PAGE	and	FRET-melting	assays.	
	 TWJ-Screena	 PAGEc	 FRET	melting	assay	
ID	 NFI	
M-[M+ligand]	
NFIb	
[S1+ligand]	
cplx.	
DT1/2	
DT1/2	
15eq.ds26	
DT1/2	
50eq.ds26	
FRETSd	
50eq.ds26	
545	 86%	 8%	(-)	 nc	 22.5	°C	 12.0	 8.0	°C	 35%	(-)	
546	 72%	 27%	(+)	 nc	 11.0	°C	 7.0	°C	 4.0	°C	 36%	(-)	
543	 63%	 40%	(++)	 -	 0.8	°C	 n.d.	 n.d.	 n.d.	
448	 55%	 21%	(+)	 nc	 15.8	°C	 8.7	°C	 8.1	°C	 51%	(+)	
459	 54%	 27%	(+)	 nc	 23.0	°C	 20.4	°C	 17.1	°C	 84%	(+++)	
460	 46%	 37%	(++)	 +	 4.2	°C	 n.d.e	 n.d.	 n.d.	
444	 43%	 39%	(++)	 +	 4.9	°C	 n.d.	 n.d.	 n.d.	
451	 42%	 118%	(++++)	 +	 10.4	°C	 8.9	°C	 8.5	°C	 82%	(+++)	
473	 35%	 80%	(+++)	 nc	 11.6	°C	 5.5	°C	 4.6	°C	 39%	(-)	
471	 33	%	 109%	(++++)	 +	 17.5	°C	 16.6	°C	 15.9	°C	 91%	(+++)	
439	 28%	 88%	(+++)	 -	 1.8	°C	 n.d.	 n.d.	 n.d.	
544	 27%	 100%	(++++)	 -	 0.6	°C	 n.d.	 n.d.	 n.d.	
415	 23%	 100%	(++++)	 -	 0	°C	 n.d.	 n.d.	 n.d.	
562	 23%	 56%	(+++)	 -	 2.0	°C	 n.d.	 n.d.	 n.d.	
414	 22%	 101%	(+++)	 -	 1.5	°C	 n.d.	 n.d.	 n.d.	
a	Selected	candidates	with	NFIM-[M+ligand]	>20%.	
b	Interaction	with	FAM	label:	“-“	for	NFI[S1+ligand]	<10%,	“+“	for	NFI[S1+ligand]	=	10-
30%,	“++“	for	NFI[S1+ligand]	=	30-50%,	“+++“	for	NFI[S1+ligand]	=	50-100%,	“++++“	for	NFI[S1+ligand]	>100%.	
c	Qualitative	PAGE	analysis:	
“nc”	 for	 non-conclusive,	 “-“	 for	 no	 detectable	 TWJ/ligand	 complex,	 “+“	 for	 detectable	 TWJ/ligand	 complex.	 	 d	 Selectivity	
determined	by	FRET:	“-“	for	FRETS	<50%,	“+“	for	
FRETS	=	50-80%,	“+++“	for	
FRETS	>80%.	
e	“n.d.”	for	not	determined	(DT1/2	<5	°C).	
	
An	improved	version	of	the	TWJ-Screen	assay.	The	TWJ-Screen	assay	allows	for	quantifying	the	
TWJ-folding	 ability	 of	 chemical	 compounds	 in	 HTS	manner.19	 This	method	 is	 based	 on	 the	 ligand-	
promoted	formation	of	a	TWJ	structure	from	a	mixture	of	the	three	separated	strands,	two	of	them	
being	 labeled	 with	 fluorophores	 (one	 with	 fluorescein	 amidite,	 or	 FAM,	 the	 other	 one	 with	
tetramethylrhodamine,	 or	 TAMRA).	 The	 ligand-promoted	 TWJ	 formation	 results	 in	 the	 FAM	 and	
	 6	
TAMRA	fluorophore	being	in	proximity	resulting	in	the	quenching	of	FAM	fluorescence	that	represents	
a	 quantitative	 measurement	 of	 TWJ	 formation.	 The	 TWJ-Screen	 protocol	 was	 slightly	 adapted	 to	
screen	wider	chemical	libraries:	the	initial	protocol	was	performed	at	room	temperature	(that	is,	in	a	
20-25	 °C	 range),	 making	 the	 temperature	 the	 only	 parameter	 left	 uncontrolled.	 For	 improving	 its	
reproducibility,	the	TWJ-screen	was	here	 implemented	at	a	 fixed	temperature	of	37	°C.	This	higher	
temperature	was	selected	since	it	allowed	for	a/	improving	the	reproducibility	of	the	assay,	lessening	
the	 unassisted	 assembly	 of	 the	 three	 separated	 strands	 into	 a	 TWJ	 structure	 (vide	 infra),	 and	 b/	
selecting	candidates	in	a	more	stringent	manner,	given	that	they	have	to	fold	and	interact	with	TWJ	in	
less	favorable	thermal	conditions.	We	screened	approximately	60	candidates/day,	using	the	initially	
described	conditions:	in	100	µL	(final	volume)	of	buffered	solution	(10	mM	lithium	cacodylate	buffer,	
pH	7.2,	supplemented	with	10	mM	KCl/90	mM	LiCl,	or	Caco.K)	were	 introduced	2	µM	of	 the	three	
strands	 initially	 introduced	by	N.	B.	Leontis	et	al.31	and	 further	studied	by	V.	Brabec	et	al.	 for	 their	
ability	to	assemble	into	a	TWJ	stable	only	upon	interaction	with	ad	hoc	ligands,22	that	is,	FAM-TWJ-S1	
(FAM-d[5’CG2A2CG2CACTCG3’]),	 TWJ-S2	 (d[5’CGAGTGCAGCGTG23’])	 and	 TWJ-S3-TAMRA	
(d[5’C2ACGCTCGT2C2G3’]-TAMRA).	 Then,	 5	molar	 equivalents	 (mol.	 equiv.,	 i.e.,	 1.0	µM)	of	 candidate	
were	 introduced	 (except	 in	 control	 wells,	 vide	 infra),	 as	 triplicates.	 The	microplate	 preparation	 is	
completed	with	6	control	wells,	i.e.,	3	wells	with	FAM-TWJ-S1	alone	(to	define	the	100%	FAM	emission)	
and	3	wells	with	the	3	separated	strands	(a	mixture	termed	«	M	»,	to	verify	the	lack	of	spontaneous	
TWJ	 folding.	 The	 microplate	 is	 centrifuged	 (30	 s),	 then	 gently	 stirred	 for	 1	 h	 at	 37	 °C	 prior	 to	
fluorescence	reading.	The	proficiency	of	candidates	to	shift	the	equilibrium	towards	the	folded	TWJ	is	
quantified	by	comparing	the	normalized	FAM	intensity	(NFI)	of	FAM-TWJ-S1	alone	(defined	as	100%)	
with	 that	of	 [FAM-TWJ-S1+ligand]	 (for	discarding	unwarranted	compound’s	 interaction	with	S1)	on	
one	hand,	and	the	NFI	of	the	mixture	M	vs.	[M+ligand]	(that	quantifies	the	TWJ	folding	per	se)	on	the	
other	 hand.	 Collected	 results	 are	 shown	 in	 Figure	 1B	 and	 Table	 1.	 The	 vast	majority	 of	 the	 1200	
compounds	 screened	 were	 found	 ineffective	 (NFIM-[M+ligand]	à0%,	 NFI[FAM-TWJ-S1+ligand]	à100%)	 but	 15	
candidates	emerged,	displaying	NFIM-[M+ligand]	values	>20%	(red	dashed	line,	Figure	1B)	(the	complete	
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TWJ-screen	results	is	provided	as	Supplementary	Material).	These	ligands,	i.e.,	compounds	414,	415,	
439,	444,	448,	451,	459,	460,	471,	473,	543,	544,	545,	546	and	562,	illustrated	all	possible	scenarios,	
from	candidates	that	display	a	good	ability	to	fold	TWJ	without	interacting	with	the	FAM	label	(flagged	
as	“++++”	in	Table	1;	e.g.,	451,	with	NFIM-[M+ligand]	=	42%	and	NFI[FAM-TWJ-S1+ligand]	>100%)	to	compounds	
with	very	high	NFIM-[M+ligand]	and	very	strong	interaction	with	FAM	label	(flagged	as	“-”in	Table	1;	e.g.,	
545,	 with	 NFIM-[M+ligand]	 =	 86%	 and	 NFI[FAM-TWJ-S1+ligand]	 =	 8%).	 The	 TWJ-Screen	 assay	 thus	 allowed	 for	
sorting	molecules	in	a	very	stringent	manner.	The	chemical	structures	of	the	15	candidates	are	shown	
in	Figure	1C.	It	is	unsurprising	to	find	previously	identified	hits,18,	19	including	the	azacyclophanes	1,5-
BisNP-O	 (451),	 2,7-BisA-O	 (459),	 2,7-BisNP-N	 (460),	 and	4,5-BisA-O	 (473)	 and	 the	azacryptand	3,3’-
TrisBP	(471),32	and	the	metallacages	Cube-DONQ	(444)	and	Prism-DONQ	(448).33	We	also	 identified	
new	candidates	(all	from	ICMUB	library)	that	all	display	well-defined	molecular	shapes	and	volumes:	
the	ruthenium	trisdiimine	complex	NQ418	(439);	two	new	triptycene	derivatives	XX-67	(543)	and	XX-
32	 (544),	whose	synthesis	will	be	described	elsewhere	 (A.Granzhan	et	al.),	 structurally	close	 to	 the	
compounds	 previously	 studied	 by	 D.	 Chenoweth	 and	 coworkers;25,	 26	 and	 a	 newly	 reported	
organometallic	cage	Rec-(AN)-DONQ	(562).34	Classical	DNA	 intercalators	are	also	 identified,	notably	
two	porphyrins,	TMPyP4	(545)35	and	TEGPy	(546),36	and	two	cationic	pyrene	derivatives,	AZ03	(414)	
and	AZ04	(415),37	owing	to	their	innate	ability	to	interact	with	negatively	charged	nucleic	acids.	
	
Confirming	the	TWJ-folding	capability	via	non-denaturing	PAGE	analyses.	To	further	investigate	
the	intrinsic	quality	of	the	15	identified	candidates,	their	TWJ-folding	capabilities	were	subsequently	
investigated	by	non-denaturing	PAGE	analysis,	according	to	the	methodology	described	by	V.	Brabec	
et	 al.22	We	 used	 the	 same	 TWJ-forming	 strands,	 TWJ-S1,	 TWJ-S2	 and	 TWJ-S3	 (without	 fluorescent	
labels).	 The	 obtained	 gels	 (15%	 polyacrylamide,	 5	µM	DNA	 loading/well),	 presented	 in	 Figure	 2A,	
offered	 a	 straightforward–but	 qualitative–reading	 of	 the	 TWJ	 folding	 ability	 of	 the	 candidates,	
visualized	by	 the	difference	of	migration	between	 the	TWJ-S1	alone	and	 the	mixture	of	 strands	M	
(lower	 dashed	 rectangle)	 and	 the	 folded	 TWJ/ligand	 complexes,	 which	 migrate	 significantly	 more	
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slowly	 (upper	 dashed	 rectangle).	 Five	 compounds	 were	 found	 efficient	 in	 these	 conditions	 (red	
arrows),	i.e.,	444,	448,	451,	460	and	471;	four	compounds	lead	to	smeared	band	(green	arrows),	i.e.,	
459,	 473,	 545	 and	 546,	 thus	 making	 conclusion	 hard	 to	 draw	 solely	 on	 the	 PAGE	 basis;	 and	 six	
compounds	were	found	inactive	(yellow	arrows),	i.e.,	414,	415,	439,	543,	544	and	562.	Given	that	PAGE	
conditions	are	known	to	be	challenging	for	non-covalent	assemblies,	these	results	underline	the	good	
TWJ-interacting	properties	of	the	5	most	efficient	compounds.		
	
	
Figure	2.	A.	PAGE	analysis	performed	with	TWJ-S1	(5.0	µM),	M	(5.0	µM)	in	absence	and	presence	of	the	top	15	
ligands	 (5	 mol.	 equiv.)	 in	 TBE	 buffer	 +	 100	mM	 NaCl,	 pH	 8.3,	 at	 4	 °C	 for	 1	 h	 (gels	 were	 post-stained	 with	
SybrGoldTM;	multiple	gels	assembled	in	a	single	image)	B-D.	FRET-melting	experiments	performed	with	F-TWJ-T	
and	the	top	15	ligands	in	either	a	comparative	(B,C)	or	competitive	manner	(C,D,	i.e.,	in	presence	of	increasing	
amounts	of	ds26	(up	to	50	mol.	equiv.))	expressed	as	DT1/2	values	(in	°C).	Best	candidates	(DT1/2	>	10	°C,	B	and	
FRETS	>	80%	in	presence	of	50	mol.	equiv.	ds26,	D)	are	highlighted	in	red.	Experiments	performed	with	0.2	µM	
DNA,	without	or	with	1.0	µM	candidates,	with	or	without	3	and	10	µM	ds26,	in	10	mM	lithium	cacodylate	plus	
10	mM	KCl/90	mM	LiCl,	pH	7.2,	between	25	and	90	°C.	E.	PAGE	analysis	of	competitive	experiments	performed	
with	TWJ	strands,	471	(2	mol.	equiv.)	and	increasing	amounts	of	ds12	(up	to	18	mol.	equiv.)	in	TBE	buffer	+	100	
mM	NaCl,	pH	8.3,	at	4	°C	for	45	min	(gels	are	post-stained	with	SybrGoldTM	for	visualizing	ds12	and	unfolded	
ds12,	i.e.,	ss12).	
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Investigating	the	TWJ-interacting	properties	via	FRET-melting	assay.	We	also	assessed	whether	
the	15	identified	ligands	interact	with	a	pre-folded	TWJ	structure.	To	this	end,	their	ability	to	stabilize	
folded	DNA	junctions	against	thermal	denaturation	was	evaluated	by	FRET-melting	assay,	using	the	
doubly	 labeled	 FAM-d[5’A(CT)2(TC)2G-T6-C(GA)2GCGAC-T6-GTCGC(AG)2T3’]-TAMRA	 system	 (FAM-TWJ-
TAMRA,	or	F-TWJ-T).35	Experiments	were	performed	as	follows:	in	100	µL	(final	volume)	of	buffered	
solution	(Caco.K),	0.2	µM	of	F-TWJ-T	in	absence	(control	wells)	or	presence	of	5	molar	equivalents	(i.e.,	
1.0	µM)	 ligands	 (as	 triplicates)	were	heated	 from	25	 to	75	 °C	 (1	 °C/step).	 The	melting	of	 the	DNA	
structure	was	monitored	through	the	FAM	emission	(quenched	at	low	temperature	due	to	the	close	
proximity	 with	 TAMRA	 in	 folded	 TWJ,	 and	 restored	 at	 elevated	 temperature	 due	 to	 the	 thermal	
unfolding	of	the	DNA	junction):	the	thermal	stability	of	F-TWJ-T,	expressed	as	its	melting	temperature	
T1/2	 (here,	T1/2	=	43.4	°C	 in	absence	of	 ligand)	 increased	up	to	63.4	°C	 in	presence	of	 the	best	TWJ-
stabilizer	(compound	459,	DT1/2	=	23.0	°C,	Table	1).	The	DT1/2	values	for	the	15	selected	compounds	are	
reported	in	Figure	2B:	only	7	of	these	candidates	(448,	451,	459,	471,	473,	545	and	546)	imparted	a	
significant	stability	(DT1/2	>10	°C,	Table	1).	Compounds	444	and	460,	yet	the	most	promising	candidates	
by	 PAGE,	 would	 have	 been	 discarded	 on	 the	 FRET-melting	 result	 basis	 (DT1/2	 =	 4.9	 and	 4.2	 °C,	
respectively);	conversely,	459,	the	most	efficient	TWJ-stabilizer	here,	lead	to	debatable	PAGE	results:	
this	discrepancy	illustrated	that	TWJ-Screen	and	FRET-melting	assays	monitored	2	different	processes	
(TWJ-folding	on	one	hand,	stabilization	of	folded	TWJ	in	the	other	hand),	thus	making	these	two	tests	
complementary.		
The	 TWJ-interacting	properties	 of	 these	 7	 candidates	were	 further	 investigated	via	 competitive	
FRET-melting	 experiments,	 to	 assess	 their	 TWJ	 selectivity	 over	 duplex-DNA.	 Experiments	 were	
performed	with	F-TWJ-T,	5	mol.	equiv.	of	ligand,	in	absence	(control	wells)	or	presence	of	15	or	50	mol.	
equiv.	 of	 a	 duplex	 competitor,	 here	 ds26	 (comprised	 of	 two	 self-complementary	 strands	 ss26	
d[5CA2TCG2ATCGA2T2CGATC2GAT2G3’]).	The	capacity	of	a	 ligand	to	withstand	the	excess	of	ds26	was	
expressed	as	FRETS	values	(FRETS=	(DT1/2[+ds26]/DT1/2[no	ds26])x100,	in	%).	Results	seen	in	Figure	2C	and	
Table	1	 indicate	 that	3	compounds	only	are	both	good	stabilizers	 (DT1/2	>10	 °C)	and	selective	 (FRETS	
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>80%),	 i.e.,	 the	 azacyclophanes	 451	 and	 459	 and	 the	 azacryptand	 471,	 making	 them	 the	 most	
promising	ligands	identified	through	this	3-step	selection	process.	Finally,	these	results	also	discarded	
the	two	porphyrins	(545	and	546)	as	false	positives,	owing	to	their	low	selectivity	(FRETS	=	35	and	36%,	
respectively),	 which	 makes	 them	 prone	 to	 interact	 with	 nucleic	 acids	 whatever	 their	 secondary	
structures.		
Of	 note,	 the	 exquisite	 selectivity	 of	 471	 (FRETS	 =	 91%,	 Table	 1)	 was	 further	 investigated	 via	 a	
competitive	PAGE	analysis	performed	with	an	excess	(2,	9	and	18	mol.	equiv.)	of	duplex-DNA	(here	
ds12,	comprised	of	two	self-complementary	strands	ss12	d[5’CGCGA2T2CGCG3’]).	Results	seen	in	Figure	
2E	confirmed	that	the	TWJ	folding	capability	of	471	withstands	the	presence	of	competitive	duplexes,	
thereby	further	demonstrating	its	selectivity	for	DNA	junctions.		
Collectively,	these	results	highlight	the	necessity	of	performing	TWJ-Screen,	PAGE	and	FRET-melting	
evaluations	in	a	stepwise	manner	to	identify	promising	ligands	on	a	reliable	basis.	In	the	present	case,	
3	compounds	passed	this	series	of	tests	successfully,	namely	the	macrocycles	451	and	459	(1,5-BisNP-
O	and	2,7-BisA-O,	respectively)	and	the	macrobicycle	471	(3,3’-TrisBP).	
	
Quantifying	the	ligand/TWJ	DNA	association	by	ESI-MS	and	equilibrium	dialysis	analyses.	We	next	
investigated	 further	 the	TWJ-interacting	properties	of	451,	459	 and	471	via	 electrospray	 ionization	
mass	spectrometry	(ESI-MS).	This	technique	provides	a	unique	opportunity	to	directly	access	both	the	
equilibrium	 affinity	 constants	 (K)	 and	 the	 stoichiometry	 of	 the	 ligand/DNA	 association,	 as	 already	
documented	with	duplex-	and	quadruplex-DNA,38	but	not	yet	applied	to	DNA	junctions.	Investigations	
were	 here	 performed	with	 both	 the	 pre-folded	 TWJ	 used	 for	 FRET-melting	 investigations	 (without	
fluorescent	 labels),	 and	 the	 duplex-DNA	 ds17	 (d[5’C2AGT2CGTAGTA2C33’]/d[5’G3T2ACTACGA2CTG23’]).	
Measurements	were	performed	 in	80:20	 (v/v)	ammonium	acetate	buffer	 (100	mM,	pH	7.0):MeOH,	
with	5	µM	DNA	and	increasing	amounts	of	ligands	(from	0	to	2	mol.	equiv.).	Results	obtained	with	471	
(Figure	 3A,	 see	 the	 supporting	 information	 for	 compounds	 451	 and	 459)	 showed	 the	 exclusive	
formation	of	 the	1:1	TWJ/471	complex,	 regardless	of	 the	DNA:ligand	ratio,	and	no	 interaction	with	
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ds17.	These	results	highlighted	a	unique	ligand	binding	site	within	the	TWJ	structure–most	likely	the	
branch	point–and	confirmed	the	exquisite	TWJ-selectivity	of	471.	Similar	experiments	performed	with	
451	and	459	showed	that	the	major	species	is	the	1:1	TWJ/ligand	complexes	as	well,	along	with	traces	
of	free	DNA	and	2:1	complexes,	and	highlighted	also	weak	and	random	interactions	with	ds17	(since	
1:1,	2:1	and	3:1	complexes	could	be	detected).	To	further	characterize	and	quantify	these	interactions,	
we	calculated	the	equilibrium	association	constants	(Table	2):39	K	values	confirmed	the	high	affinity	of	
451,	459	and	471	for	TWJ	(K	between	3.9x106	and	1.9x109	M-1)	along	with	their	excellent	selectivity	
over	duplex-DNA	(>2-log	difference).			
	
	
Figure	3.	A.	ESI-MS	profiles	of	the	association	of	TWJ	(left	panels)	or	ds17	(right	panels)	with	increasing	amounts	
(0,	1	and	2	mol.	equiv.)	of	471.	Experiments	performed	with	5.0	µM	DNA,	without	or	with	5.0	or	10	µM	ligand,	
in	100	mM	ammonium	acetate,	pH	7.2,	after	1-h	equilibration	at	25	°C.	B.	Equilibrium	dialysis	results	for	451,	459	
and	471	(black	bars:	free	ligand,	brown	bar:	ligand	bound	to	TWJ,	orange	bar:	ligand	bound	to	ds17).	Experiments	
performed	with	75	µM	DNA	(base	pairs),	without	or	with	2	µM	ligand,	in	sodium	phosphate	+	100	mM	NaCl,	pH	
7.2,	after	24-h	equilibration	at	25	°C.	C.	Viability	profiles	obtained	via	the	SRB	assay	with	451,	459	and	471	after	
72	h-incubation	(37	°C,	DMEM)	with	MCF7	(brow	line)	and	MDA-MB-231	(orange	line)	cells.	
	
We	next	decided	to	confirm	these	results	by	an	alternative	technique,	performed	in	solution,	and	
selected	 the	 equilibrium	 dialysis	 (or	 competition	 dialysis)	 that	 has	 been	 already	 applied	 to	 a	wide	
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variety	of	DNA	structures	(single-stranded	and	double-stranded-DNA,	triplex-	and	quadruplex-DNA),40	
but	not	to	DNA	junctions.	In	this	experiment,	both	TWJ	and	ds17,	isolated	from	the	main	solution	in	
semi-permeable	chambers	(200	µL	at	75	µM,	expressed	in	base-pairs)	were	dialyzed	against	solution	
of	 ligands	 (200	mL	at	2	µM).	After	equilibration	 (24	h,	25	 °C),	 the	amount	of	 ligand	bound	to	each	
structure	is	quantified	by	fluorescence	titration	of	the	content	of	the	dialysis	chambers,	after	leaking	
the	 ligand	 by	 1%	 sodium	 dodecyl	 sulfate	 SDS	 treatments	 (versus	 a	 quantification	 of	 the	 ligand	
remaining	in	the	dialysis	solution).	Results	presented	in	Figure	3B	showed	the	preferred	fixation	of	the	
ligands	onto	TWJ,	but	also	emphasized	the	better	selectivity	of	471	as	compared	to	451	and	459.	Again,	
we	quantified	these	interactions	through	the	calculations	of	the	apparent	affinity	constant	Kapp	(Table	
2):40	they	confirmed	the	high	affinity	of	451,	459	and	471	for	TWJ	(Kapp	between	6.0x106	and	1.4x107	
M-1)	along	with	their	good	(451	and	459)	to	excellent	selectivity	over	duplex-DNA	(>2-log	difference	
for	471).			
	
Preliminary	cell-based	assays	with	451,	459	and	471.	After	the	thorough	evaluation	of	their	TWJ-
interacting	properties	in	vitro,	we	decided	to	evaluate	the	antiproliferative	properties	of	451,	459	and	
471	against	cancer	cells.	Their	cellular	activity	was	evaluated	on	two	cancer	cell	lines,	MCF7	and	MDA-
MB-231,	which	are	extensively	used	in	the	study	of	experimental	therapeutics	since	they	represent	
two	 different	 classes	 of	 breast	 cancers:	 MCF-7	 are	 derived	 from	 a	 hormone-responsive	 cancer,	
expressing	estrogen	(ER),	progesterone	(PR)	and	glucocorticoid	receptors	(GR);	MDA-MB-231	cells	are	
representative	of	triple	negative	breast	cancers	(ER-,	PR-	and	HER2-	(human	epidermal	growth	factor	
receptor	2)),	which	are	typically	more	aggressive	and	challenging	to	cure.	In	addition,	MCF7	and	MDA-
MB-231	are	instrumental	for	the	evaluation	of	DNA	damaging	agents	since	they	have	functional	and	
mutant	p53,	 respectively,	a	critical	protein	controlling	DNA	damage	checkpoints	and	mediating	cell	
cycle	 arrests	 and/or	 apoptosis	 in	 response	 to	 DNA	 damage.	 Viability	 analysis	was	 performed	 here	
through	 the	 sulforhodamine	 B	 (SRB)	 test41,42	 and	 collected	 results	 were	 compared	 to	 the	 firmly	
established	anticancer	(and	DNA	damaging)	agent	camptothecin	(Figure	S4).43	To	this	end,	cells	were	
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incubated	 for	 72	 h	 at	 37	 °C	 in	 DMEM	without	 or	 with	 ligand,	 prior	 to	 fixation	 with	 a	 solution	 of	
trichloroacetic	acid	10%	(1	h	at	4	°C).	After	supernatant	removal,	a	solution	of	SRB	(0.2%	in	1%	acetic	
acid)	was	added	for	30	min	before	being	washed	(acetic	acid	1%)	and	dried.	A	solution	of	Tris	base	(10	
mM)	 was	 then	 added	 to	 allow	 for	 optical	 density	 reading	 (at	 530	 nm)	 to	 assess	 cell	 viability	 and	
determine	 the	 lethal	 dose	 (LD50,	 the	 concentration	 at	 which	 50%	 of	 the	 cell	 growth	 inhibition	 is	
reached).		
	
Table	2.	Quantification	of	DNA	interactions	(ESI-MS	and	dialysis)	and	toxicity	(SRB)	of	top	3	TWJ-ligands.	
	 ESI-MS	(K,	M-1)a	 Equilibrium	dialysis	(Kapp,	M
-1)	 SRB	test	(LD50,	µM)	
ID	 TWJ	 ds	 TWJ/ds	 TWJ ds TWJ/ds	 MCF7 MDA	 BJ-hTERT	
451	 4.7x107	 7.5x104	 >2-log	 8.7x106	 5.9x105	 >1-log	 0.10	 0.16	 0.04	
459	 1.9x109	 3.1x104	 >4-log	 1.4x107	 3.8x105	 >1-log	 4.80	 2.80	 1.00	
471	 3.9x106	 7.5x103	*	 >2-log*	 6.0x106	 4.7x104	 >2-log	 1.30	 1.30	 2.60	
a	K	calculations	on	the	basis	of	experiments	performed	with	10	µM	DNA	and	20	µM	ligands.	*	no	ds17/471	interactions	
detected	at	1:2	ratio;	Ka	calculated	for	experiments	performed	at	1:3	DNA/ligand	ratio.	
	
The	results	(Figure	3C	and	Table	2)	showed	that	the	cellular	activity	stood	in	the	same	range	for	
both	cells	lines,	with	a	higher	inhibition	properties	for	451	(with	LD50	=	0.10	and	0.16	µM	for	MCF7	and	
MDA-MB-231,	respectively),	then	for	471	(LD50	=	1.30	and	1.30	µM)	and	for	459	(LD50	=	4.80	and	2.80	
µM).	In	these	conditions,	451	displayed	a	higher	activity	than	camptothecin	(with	LD50	=	1.70	and	1.40	
µM),	 which	 is	 here	 found	 comparable	 to	 471.	 For	 sake	 of	 comparison,	 we	 also	 performed	 SRB	
investigations	with	normal	fibroblasts	(BJ-hTERT),	as	models	of	healthy	cells.44	As	seen	in	Table	2,	only	
471	was	found	less	toxic	in	BJ-hTERT	than	in	cancer	cells	(2-fold	difference,	with	LD50	=	1.30	and	2.60	
µM	for	cancer	cells	and	BJ-hTERT,	respectively),	making	it	the	most	promising	compound	from	that	
series	 of	 ligands.	 To	 gain	 insights	 into	 the	 capacity	 of	 471	 to	 trigger	 DNA	 damage,	we	 performed	
preliminary	 immunodetection	 studies	using	an	antibody	 raised	against	 the	phosphorylated	histone	
H2AX	(so	called	gH2AX),	an	established	marker	of	DNA	damage.45	The	pilot	study	was	carried	out	with	
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MCF7	treated	with	471	and	camptothecin	as	control.	Collected	images	seen	in	Figure	S5	confirmed	
that	the	ligands	triggered	a	marked	accumulation	of	gH2AX	foci.	These	preliminary	data	thus	provide	
an	encouraging	sign	for	the	future	of	this	new	class	of	non-canonical	DNA	structure-targeting	ligands	
as	DNA	damaging	agents,	and	efforts	are	now	invested	to	establish	a	firm	link	between	cellular	TWJ	
interaction	and	DNA	damage.		
	
Conclusion.	
Compared	to	normal	cells,	cancer	cells	harbor	a	flawed	repertoire	of	DNA	damages	signaling	and	
repair	capabilities,	collectively	known	as	DNA	damage	response,	or	DDR.1-6	Three	main	aspects	of	DDR	
differ	from	cancer	to	healthy	cells:	i-	the	loss	of	one	or	more	DDR	pathways,	ii-	an	increased	level	of	
replicative	 stress	 and	 iii-	 endogenous	 DNA	 damages.46	 These	 aspects	 thus	 provide	 a	 window	 of	
therapeutic	opportunities	for	compounds	that	trigger	or	exacerbate	cellular	crisis	states.	Our	approach	
is	here	focused	on	compounds	that	stabilize	three-way	DNA	junctions	(TWJ),	given	that	these	higher-
order	DNA	structures	represent	topological	hindrances	to	polymerase	that	can	hamper	proper	DNA	
transactions	(replication,	transcription).9	The	TWJ-ligands	could	thus	represent	a	novel	and	promising	
class	of	crisis-inducing	agents.		
To	identify	promising	TWJ-ligands,	we	developed	and	report	here	on	a	validation	framework	that	
comprises	6	complementary	in	vitro	assays:	1-	the	TWJ-Screen	assay,	which	allowed	for	evaluating	the	
ability	to	promote	the	TWJ	folding	of	1200	compounds;	2-	a	PAGE	analysis,	which	confirms	the	TWJ-
folding	ability	of	the	15	identified	candidates	in	more	stringent	conditions;	3-	the	FRET-melting	assay,	
which	 provide	 insights	 into	 both	 the	 TWJ-stabilizing	 properties	 and	 selectivity	 of	 the	 identified	
candidates;	4-	an	ESI-MS	 investigations,	which	further	studied	TWJ-selectivity	and	gives	access	to	a	
quantification	(affinity	constants,	Ka)	of	the	ligand/DNA	association;	5-	the	equilibrium	dialysis,	which	
provides	 an	 alternative	 quantification	 of	 the	 ligand/DNA	 binding	 parameters;	 and	 6-	 the	 SRB	 test,	
which	assesses	the	antiproliferative	activity	of	identified	TWJ-ligands	against	human	breast	cancer	cells	
(MCF7	and	MDA-MB-231).		
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Collectively,	the	wealth	of	data	collected	in	the	course	of	this	study	highlights	the	strength	of	our	
methodology	to	uncover	TWJ-ligands,	with	the	identification	of	3	promising	compounds	here,	i.e.,	451,	
459	and	471,	whose	properties	make	them	ideally	suited	to	be	used	as	prototype	ligands	throughout	
the	validation	chain.	Exploring	their	use	as	anticancer	agents	will	require	to	decipher	the	mechanisms	
underlying	their	antiproliferative	properties.	Also,	our	results	highlight	the	need	for	screening	wider	
chemical	 libraries	 to	 uncover	 ever	 more	 efficient	 TWJ-ligands	 and	 we	 are	 convinced	 that	 the	
framework	described	here	is	an	ideal	toolbox	to	do	so.	Importantly,	libraries	to	be	tested	must	not	be	
focused	on	drug-like	compounds	or	small-molecules	only	(like	the	Pathogen	Box®	or	the	CNE)	but	must	
include	chemicals	with	defined	shapes	and	volumes,	given	that	it	appears	to	be	a	major	determinant	
of	efficient	TWJ-ligands.	Indeed,	thanks	to	the	pioneering	investigations	of	M.	J.	Hannon	and	coworkers	
performed	 with	 iron	 supramolecular	 cylinders,20-24	 we	 known	 that	 the	 privileged	 binding	 site	 for	
compounds	within	the	TWJ	structure	is	the	branch	point,	a	cavity	that	results	from	the	convergence	of	
three	duplex	arms.	This	cavity	is	hydrophobic	owing	to	its	side-walls	made	of	base-pairs	(here	two	T=A	
and	one	G≡C	base	pairs),	thus	being	suited	to	accommodate	sterically	demanding	ligands	displaying	
large	aromatic	moieties.	This	was	confirmed	here	through	the	unveiling	of	3	promising	candidates,	the	
azacyclophanes	451	and	459	(1,5-BisNP-O	and	2,7-BisA-O,	respectively)	and	the	azacryptand	471	(3,3’-
TrisBP),	 which	 all	 display	 well-defined	 three-dimensional	 structures	 and	 large	 aromatic	 moieties	
(naphthalene,	acridine	and	bipyridine)	prone	to	interact	efficiently	with	the	cavity	walls.	These	results	
thus	provide	new	perspectives	on	and	further	insights	into	the	cellular	activity	of	the	azacyclophanes	
and	azacryptands,	which	could	originate	in	multiple	dysregulated	pathways	(TWJ-interaction	as	well	
as	interactions	with	abasic	sites	and	cleavage	and	inhibition	of	DNA	repair).47,48	They	also	contribute	to	
expand	the	portfolio	of	DNA	binders	with	promising	anticancer	properties	and	the	panoply	of	DNA	
structure	targets	with	high	therapeutic	value.			
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Experimental	section	
Chemicals.	 The	 open	 access	 Pathogen	 Box®	 comprises	 400	 compounds	 with	 biological	 activity	
against	specific	pathogenic	organisms.	The	box	is	provided	by	the	Medicines	for	Malaria	Venture	as	an	
open	 access	 compound	 collection	 (http://www.pathogenbox.org/).	 The	 chimiothèque	 nationale	
essentielle	is	a	collection	of	640	compounds	assembled	by	and	purchased	from	the	French	National	
chemolibrary	 (http://chimiotheque-nationale.cn.cnrs.fr/).	 All	 other	 chemicals	 have	 been	 prepared	
according	to	methodologies	described	(with	purity	≥95%	as	evaluated	by	elemental	analyses	or	HPLC-
MS)	 in	 the	 corresponding	 references,	 except	 camptothecin	 (99.8%	 purity),	 purchased	 from	
Selleckchem.	
	
Table	3.	Oligonucleotides	used	in	this	study	
Status	 Nature	 Name	 Sequence	
Labeled	 TWJ	 FAM-TWJ-S1	 FAM-d[5’CG2A2CG2CACTCG
3’]	
TWJ-S3-TAMRA	 d[5’C2ACGCTCGT2C2G
3’]-TAMRA	
F-TWJ-T	 FAM-d[5’A(CT)2(TC)2G-T6-C(GA)2GCGAC-T6-GTCGC(AG)2T
3’]-TAMRA	
Unlabeled	 TWJ	 TWJ-S1	 d[5’CG2A2CG2CACTCG
3’]	
TWJ-S2	 d[5’CGAGTGCAGCGTG2
3’]	
TWJ-S3	 d[5’C2ACGCTCGT2C2G
3’]-	
TWJ	 d[5’A(CT)2(TC)2G-T6-C(GA)2GCGAC-T6-GTCGC(AG)2T
3’]	
duplex	 ds12	
self-complementary	
strand	1:	d[5’CGCGA2T2CGCG
3’]	
strand	2:	d[5’CGCGA2T2CGCG
3’]	
ds17	 strand	1:	d[5’CCAGTTCGTAGTAACCC3’]	
strand	2:	d[5’GGGTTACTACGAACTGG3’]	
ds26	 strand	1:	d[5’CAATCGGATCGAATTCGATCCGATTG3’]	
self-complementary	 strand	2:	d[5’GTTAGCCTAGCTTAAGCTAGGCTAAC3’]	
	
	
Oligonucleotides.	The	lyophilized	DNA	sequences	(Table	3),	purchased	from	EurogentecTM	(Seraing,	
Belgium)	 were	 firstly	 diluted	 at	 500	 μM	 in	 deionized	 water	 (18.2	 MΩ.cm	 resistivity).	 The	 actual	
concentration	of	each	DNA	solution	was	determined	after	a	dilution	to	1	μM	theoretical	concentration	
through	UV	spectral	analysis	at	260	nm	(after	5	min	at	90	°C)	with	the	molar	extinction	coefficient	
values	 provided	 by	 the	 manufacturer.	 Separated	 strands	 (FAM-TWJ-S1,	 TWJ-S1,	 TWJ-S2,	 TWJ-S3-
TAMRA	and	TWJ-S3)	were	subsequently	diluted	in	a	CacoK	buffer	(10	mM	lithium	cacodylate	buffer	
plus	10	mM	KCl/90	mM	LiCl	pH	7.2)	at	2	μM	for	TWJ-Screen	and	9	μM	for	PAGE	experiments.	For	FRET-
melting	 experiments,	 the	 higher-order	 DNA	 structures	 of	 both	 FAM-TWJ-TAMRA	 and	 ds26	 were	
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prepared	by	mixing	40	μL	of	the	constitutive	strand	(500	μM)	with	8	μL	of	a	lithium	cacodylate	buffer	
solution	(100	mM,	pH	7.2),	plus	8	μL	of	a	KCl/LiCl	solution	(100	mM/900	mM)	and	24	μL	of	water.	For	
ESI-MS	analysis,	the	higher-order	DNA	structure	was	prepared	by	mixing	17	μL	of	TWJ	(500	μM)	with	
17	μL	of	ammonium	acetate	buffer	(1	M,	pH	7.0)	and	136	μL	of	water.	The	higher-order	structures	
were	folded	according	to	two	procedures:	(a)	for	FAM-TWJ-TAMRA	(FRET-melting)	and	TWJ	(ESI-MS),	
solutions	were	heated	(90	°C,	5	min),	cooled	on	ice	(FRET-melting)	or	to	25	°C	gradually	(ESI-MS)	and	
then	stored	at	least	overnight	(4	°C);	(b)	for	ds26,	the	solutions	were	heated	(90	°C,	5	min),	gradually	
cooled	(65,	60,	55,	50,	40	and	30	°C	(60	min/step),	25	°C	(2	h))	and	then	stored	overnight	(4	°C).		
	
TWJ-Screen	assay.	Experiments	are	performed	in	a	96-well	format	plate	(Greiner,	F-bottom	black)	
using	 a	 BMG	 Labtech	 ClarioStar	 equipped	with	 FAM	 filters	 (lex=	 492	 nm;	lem=516	 nm)	 at	 37°C.	
Experiments	are	performed	in	CacoK	buffer	(10	mM	lithium	cacodylate	plus	10	mM	KCl/90	mM	LiCl,	
pH	 7.2,	 final	 volume:	 100	µL/well)	 with	 1	µM	 ligand	 (10	µL	 of	 10	µM	 solution)	 and	 0.2	µM	DNA	
(stepwise	 addition	 of	 10	 µL	 of	 2	 µM	 solution	 of	 FAM-TWJ-S1,	 TWJ-S2	 and	 TWJ-S3-TAMRA).	 The	
microplate	is	centrifuged	quickly	(30	s)	and	then	placed	into	the	ClarioStar.	The	FAM	fluorescence	is	
monitored	upon	gentle	stirring	at	37	°C	every	5	min	during	1	h.	Final	data	are	analyzed	by	using	Excel	
(Microsoft	 Corp.)	 and	 OriginPro®9	 (OriginLab	 Corp.):	 the	 results	 are	 expressed	 as	 normalized	
fluorescence	 intensity	 (NFI)	 values	 collected	 at	 60	 min.	 The	 efficiency	 of	 ligands	 to	 fold	 TWJ	 is	
quantified	by	comparing	the	NFI	of	FAM-TWJ-S1	alone	(defined	as	100%)	versus	that	of	[FAM-TWJ-
S1+ligand]	(for	discarding	unwarranted	ligand’s	interaction	with	FAM-TWJ-S1)	on	one	hand,	and	the	
NFI	of	the	mixture	M	([FAM-TWJ-S1+TWJ-S2+TWJ-S3-TAMRA])	versus	[M+ligand]	(that	quantifies	the	
TWJ	folding	per	se)	on	the	other	hand.	Reported	NFI	values	are	means	of	3	experiments.	
	
FRET-melting	assay.	Experiments	are	performed	in	a	96-well	format	plate	(Agilent)	using	an	Agilent	
Stratagene	Mx3005P	equipped	with	FAM	filters	 (lex=	492	nm;	lem=516	nm)	 from	25	 °C	 to	90	 °C.	
Experiments	are	performed	in	CacoK	buffer	(10	mM	lithium	cacodylate	plus	10	mM	KCl/90	mM	LiCl,	
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pH	7.2,	final	volume:	100	µL/well)	with	0.2	µM	DNA	(the	labelled	sequence	FAM-TWJ-TAMRA	and	with	
1	µM	ligand	(1	µL	of	100	µM	solution).	The	microplate	is	centrifuged	quickly	(10	s),	gently	stirred	for	
30	min	 at	 25	 °C,	 centrifuged	 quickly	 (10	 s)	 again	 and	 then	 placed	 into	 the	Mx3005P.	 After	 a	 first	
equilibration	step	(25	°C,	30	s),	a	stepwise	increase	of	1	°C	every	30	s	for	65	cycles	to	reach	90	°C	was	
performed,	and	measurements	were	made	after	each	cycle.	Final	data	were	analyzed	with	Excel	and	
OriginPro®9.	The	emission	of	FAM	was	normalized	(0	to	1),	and	T1/2	was	defined	as	the	temperature	
for	 which	 the	 normalized	 emission	 is	 0.5;	 reported	 ΔT1/2	 values	 are	 means	 of	 3	 experiments.	
Competitive	experiments	are	performed	similarly,	that	is,	with	labelled	DNA	(FAM-TWJ-5dhp-TAMRA,	
0.2	μM)	in	presence	of	ligand	(1.0	μM,	5	mol.	equiv.)	and	increasing	amounts	(3.0	and	10.0	μM,	15	and	
50	mol.	equiv.)	of	the	unlabeled	competitor	ds26.	
	
Polyacrylamide	 gel	 electrophoresis.	 Non-denaturing	 polyacrylamide	 gel	 electrophoresis	 (PAGE)	
was	performed	according	to	the	protocol	described	by	J.	Malina	et	al.22,	 in	15%	polyacrylamide	gel	
(prepared	by	mixing	6.8	mL	of	acrylamide	(40%),	11.2	mL	of	TBE	buffer,	180	µL	of	APS	(10%	w/v)	and	
18	µL	of	TEMED;	15	min-polymerization).	Samples	were	prepared	in	15μL	(volume)	comprising	15	μL	
DNA	or	DNA/ligand	mixes	plus	3	µL	of	DNA	loading	dye	(6X).	Each	solution	was	prepared	separately:	
TWJ-S1	alone	(6	µM),	[TWJ-S1+TWJ-S2+TWJ-S3]	(or	M)	(6	µM),	[M	(6	µM)	+1	mol.	equiv.	ligand	(6	µM)],	
[M	(6	µM)	+2	mol.	equiv.	ligand	(12	µM)],	[M	(6	µM)	+3	mol.	equiv.	ligand	(18	µM)],	[M	(6	µM)	+5	mol.	
equiv.	ligand	(30	µM)]	and	[TWJ-S1+TWJ-S2]	(6	µM);	the	solutions	were	stirred	for	1	hour	at	25	°C	prior	
the	addition	of	3	µL	of	DNA	loading	dye	(6X).	These	mixes	were	stirred	for	15	min	at	25	°C	(a	period	
during	which	the	gel	is	stacked	at	7	W	(150-180	V,	43-38	mA)	in	TBE	buffer	enriched	with	100	mM	NaCl,	
pH	8.3)	prior	the	loading	of	12	µL/well	of	each	solution	and	1	h-migration	at	7W.	After	the	migration,	
gels	were	analyzed	after	a	post-staining	step	(SYBR®	Gold	solution,	1:10000,	10	min,	25°C	under	gentle	
agitation)	with	a	UVP	MultiDoc-It®	 imaging	system	(λex	=	302	nm).	Competitive	PAGE	experiments	
were	performed	according	to	a	similar	protocol	but	including	FAM-TWJ-S1	(instead	of	the	unlabeled	
TWJ-S1).	15	µL	of	following	solutions	were	prepared:	ds12	alone	(Table	3)	alone	(252	µM-nt),	M	alone	
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(252	µM-nt),	[M	(252	µM-nt)	+2	mol.	equiv.	ligand	(12	µM)],	[M	(252	µM-nt)	+2	mol.	equiv.	ligand	(12	
µM)	+		1	mol.	equiv.	ds12	(252	µM-nt	)],	[M	(252	µM-nt)	+2	mol.	equiv.	ligand	(12	µM)	+	5	mol.	equiv.	
ds12	(1260	µM-nt)],	[M	(252	µM-nt)	+	2	mol.	equiv.	ligand	(12	µM)	+	10	mol.	equiv.	ds12	(2520	µM-
nt)].	The	solutions	were	stirred	for	1	hour	at	25	°C	prior	the	addition	of	3	µL	of	sucrose	48%.	These	
mixes	were	stirred	for	15	min	at	25°C	prior	the	loading	of	12	µL/well	of	each	solution	and	50	minutes	
migration	 at	 7	W.	 After	 the	migration,	 gels	were	 post-stained	 (SYBR®	Gold	 solution,	 1:10000)	 and	
imaged	with	the	MultiDoc-It®	(λex	=	302	nm).		
	
ESI-MS	analysis.	Electrospray	mass	spectrometry	experiments	were	performed	on	a	LTQ	Orbitrap	
XL	(Thermo	Scientific)	spectrometer	equipped	with	Ion	Max	source	and	HESI-II	probe	in	the	negative	
ion	mode.	TWJ	and	ds17	alone	as	well	as	the	corresponding	DNA:ligand	mixtures	(1:1	and	1:2	mol.	
equiv.)	were	prepared	in	100	mM	ammonium	acetate	buffer	and	equilibrated	at	25	°C	for	1	hour.	To	
obtain	a	stable	electrospray	signal,	20%	of	methanol	were	added	to	the	solution	just	before	injection.	
The	 solutions	were	 injected	with	 syringe	pump	at	a	 flow	 rate	of	5	µL/min.	 The	 full	 scan	mass	was	
recorded	in	600-4000	m/z	range.	The	following	tuning	parameters	were	used:	heater	temperature	=	
50	°C,	spray	voltage	=	4.0	kV,	capillary	temperature	=	275	°C,	Tube	lens	=	-160.00	(negative	ion	mode)	
and	 the	 capillary	 voltage	 varied	 between	 -35.00	 V	 and	 -60.00	 V.	Quantification	 of	 the	 equilibrium	
affinity	 constants	 (K)	 of	 ligands	 for	 either	 TWJ	or	 ds17	has	 been	done	 according	 to	 the	procedure	
described	by	F.	Rosu	et	al.39		
	
Competition	Equilibrium	Dialysis.	The	oligonucleotide	solutions	of	TWJ	and	ds17	were	prepared	as	
75	µM	(base	pair)	concentration	in	111	mM	NaCl	solution.	These	solutions	were	then	heated	at	90	°C	
for	5	minutes,	cooled	down	slowly	to	25	°C	and	left	at	4	°C	overnight.	For	each	dialysis	experiment	
were	used	 four	dialysis	units	 (Slide-A-Lyzer®	MINI	Dialysis	Units,	molecular	weight	cut-off:	3.5	kDa)	
previously	washed	with	milli-Q	water.	Two	of	them	were	filled	with	200	µL	of	TWJ	DNA	solution	and	
the	other	two	bags	with	200	µL	of	the	solution	of	duplex	DNA	ds17.	Dialysis	units	were	then	placed	
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into	a	beaker	containing	200	mL	of	2-2.5	µM	solution	of	tested	ligand	enriched	with	111	mM	of	NaCl,	
covered	with	parafilm	and	aluminum	foil	and	allowed	to	equilibrate	for	24	h	at	room	temperature.	The	
solutions	from	each	dialysis	unit	were	then	transferred	to	Eppendorf	tubes.	The	content	of	each	bag	
was	then	mixed	with	sodium	dodecyl	sulfate	solution	(10%)	to	reach	a	1%	SDS	concentration	(v/v).	The	
concentrations	of	free	product	in	the	dialysate	solution	and	product	concentrations	in	the	dialysis	bags	
were	determined	by	fluorescence	measurements	using	the	molar	extinction	coefficients	of	the	ligand	
(determined	in	the	presence	and	absence	of	the	detergent,	see	Tables	4	and	5	respectively)	and	finally,	
the	apparent	association	constants	(Kapp)	were	calculated	according	to	formula:40	Kapp	=	[L-NA]/[NA][L],	
expressed	in	M-1,	in	which	[L-NA]	is	the	concentration	of	ligand	bound	to	nucleic	acid	determined	as	a	
difference	between	total	 ligand	concentration	 inside	the	dialysis	unit	and	free	 ligand	concentration	
(dialysate	solution);	[NA]	is	the	concentration	of	free	DNA	calculated	as	a	difference	between	initial	
concentration	of	nucleic	acid	and	[L-NA];	and	[L]	is	the	free	ligand	concentration	(dialysate	solution).					
	
Table	4.	Extinction	coefficients	of	tested	ligands.	
	
	
Table	5.	Molar	fluorescent	extinction	coefficients	of	tested	ligands.	
	
Cell	Culture.	MCF7	(breast	adenocarcinoma)	and	MDA-MB-231	(breast	adenocarcinoma)	cells	were	
routinely	cultured	in	75	cm2	tissue	culture	flasks	(Nunc™)	at	37	°C	in	a	humidified,	5%	CO2	atmosphere	
in	 Dulbecco’s	 Modified	 Eagle	Medium	 (DMEM)	 supplemented	 with	 10%	 fetal	 bovine	 serum	 (FBS,	
Gibco)	and	1%	Penicillin-Streptomycin	(Pen-Strep,	5.0	u.mL-1	Pen/5.0	µg.mL-1	Strep,	Gibco)	mixture.	
Same	culture	conditions	were	used	for	BJ-hTERT,	normal	foreskin	fibroblasts	immortalized	by	hTERT	
Ligand	 Excitation	wavelength	
Emission	
wavelength	
Molar	Fluorescence	Extinction	Coefficient	
[mol-1×L-1×cm-1]	
451	 285	nm	 330	nm	 2.33×109	
459	 300	nm	 400	nm	 4.74×108	
471	 200	nm	 319	nm	 9.38×108	
Ligand	 Excitation	wavelength	
Emission	
wavelength	
Molar	Fluorescence	Extinction	Coefficient	
[mol-1×L-1×cm-1]	
451	 285	nm	 335	nm	 3.91×109	
459	 300	nm	 400	nm	 1.07×109	
471	 200	nm	 318	nm	 6.58×108	
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transduction,	 except	 that	 the	 growth	 medium	 was	 a	 4:1	 mixture	 of	 DMEM	 and	 M199	 medium	
supplemented	with	15%	FBS	and	Pen-Strep.	Cells	were	 subcultured	 twice	a	week	using	a	 standard	
protocol:	the	medium	was	first	removed	by	aspiration;	the	cells	were	subsequently	washed	once	with	
Dulbecco's	 Phosphate	 Buffered	 Saline	 (DPBS)	 and	 1.5	mL	 of	 a	 trypsin	 solution	 (0.25%,	 Gibco)	was	
added.	 After	 5min	 at	 37	 °C,	 cells	 were	manually	 harvested	 and	 500	µL	 of	 the	 solution	 of	 cells	 in	
suspension	was	dispensed	into	three	cell	culture	flasks	containing	10	mL	of	DMEM	medium	(with	10%	
FBS	and	1%	Pen-Strep).	
	
Cell	proliferation	SRB	assay.	The	antiproliferative	properties	of	the	ligands	were	assessed	through	
the	sulforhodamine-B	(SRB)	assay,	according	to	the	protocols	described	by	V.	Vichai	&	K.	Kirtikara	and	
P.	Skehan	et	al.41,42	Cells	were	seeded	in	a	96-well	plate	(6000	cells/well)	in	160	µL	of	growth	medium	
for	24	h	at	37	°C.	Then,	40	μL	of	ligand	solution	were	added	to	reach	the	final	concentration	of	the	
ligands	between	500	and	0.05	μM	or	50	and	0.005	μM	and	incubated	for	72	h	at	37	°C.	After	72	h,	the	
media	was	removed	and	the	cells	fixed	with	a	solution	of	trichloroacetic	acid	10%	(150	µL,	1	h	at	4	°C).	
The	supernatant	was	removed,	the	fixed	cells	were	washed	with	water	and	then	dried.	A	solution	100	
μL	of	SRB	(0.2%	in	1%	acetic	acid)	was	added	into	each	well	(except	control	wells);	after	30	min,	the	
supernatant	was	removed,	the	wells	were	washed	3	times	with	150	µL	of	acetic	acid	(1%)	and	dried.	
After	that,	150	µL	of	Tris	base	(10	mM)	were	added	in	each	well	and	the	microplate	gently	stirred	for	
5	min	at	25	°C.	Optical	density	(OD)	values	were	determined	at	530	nm.	Final	data	were	analyzed	with	
Excel	(Microsoft	Corp.)	and	GraphPad7.0	(Prism	software):	the	OD530nm	was	normalized	(from	0	to	100;	
0	for	ligand	untreated,	SRB	unstained	cells	and	100	for	ligand	untreated,	SRB	stained	cells),	and	LD50	
(lethal	 dose,	 defined	 as	 the	 concentration	 at	 which	 50%	 of	 the	 cell	 growth	 inhibition	 is	 reached)	
determined	for	a	normalized	OD530nm	of	50%;	reported	LD50	values	are	means	of	3	experiments.	
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